We are live on ! Find out more
CS

Candriam SCA Portfolio holdings

AUM $19.3B
1-Year Est. Return 39.18%
This Fund
S&P 500
This Quarter Est. Return
+5.62%
1 Year Est. Return
+39.18%
3 Year Est. Return
+109.85%
5 Year Est. Return
+149.31%
10 Year Est. Return
+617.16%
AUM
$16.5B
AUM Growth
+$861M
Cap. Flow
+$217M
Cap. Flow %
1.32%
Top 10 Hldgs %
30.08%
Holding
735
New
44
Increased
335
Reduced
212
Closed
49

Top Buys

Rank Stock Value
1
LLY icon
Eli Lilly
LLY
+$60.1M
2
QCOM icon
Qualcomm
QCOM
+$53.4M
3
NU icon
Nu Holdings
NU
+$48.5M
4
AMZN icon
Amazon
AMZN
+$46.5M
5
BMA icon
Banco Macro
BMA
+$43.2M

Top Sells

Rank Stock Value
1
AAPL icon
Apple
AAPL
+$40.8M
2
ADBE icon
Adobe
ADBE
+$36.1M
3
VIPS icon
Vipshop
VIPS
+$33.1M
4
SBUX icon
Starbucks
SBUX
+$31.4M
5
LOW icon
Lowe's Companies
LOW
+$29.1M

Sector Composition

Rank Sector Weight
1 Technology 33%
2 Healthcare 27.47%
3 Financials 9.69%
4 Consumer Discretionary 7.72%
5 Industrials 6.66%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BBIO icon
651
BridgeBio Pharma
BBIO
$16.5B
– –
-380,000
Closed -$11.7M
CABA icon
652
Cabaletta Bio
CABA
$444M
– –
-200,000
Closed -$3.41M
CRNX icon
653
Crinetics Pharmaceuticals
CRNX
$8.87B
– –
-88,005
Closed -$4.12M
EDU icon
654
New Oriental
EDU
$7.94B
– –
-11,700
Closed -$7.99M
EPAM icon
655
EPAM Systems
EPAM
$4.92B
– –
-2,707
Closed -$748K
EPR icon
656
EPR Properties
EPR
$4.85B
– –
-91,196
Closed -$3.87M
EVH icon
657
Evolent Health
EVH
$429M
– –
-185,228
Closed -$6.07M
FDMT icon
658
4D Molecular Therapeutics
FDMT
$543M
– –
-269,000
Closed -$8.57M
FOLD
659
DELISTED
Amicus Therapeutics
FOLD
– –
-799,823
Closed -$9.42M
HAE icon
660
Haemonetics
HAE
$3.63B
– –
-5,316
Closed -$454K
HHH icon
661
Howard Hughes
HHH
$3.93B
– –
-84,946
Closed -$5.88M
INGR icon
662
Ingredion
INGR
$6.4B
– –
-2,000
Closed -$234K
IRON icon
663
Disc Medicine
IRON
$2.85B
– –
-80,000
Closed -$4.98M
KALV
664
DELISTED
KalVista Pharmaceuticals
KALV
– –
-350,000
Closed -$4.15M
KBH icon
665
KB Home
KBH
$3.53B
– –
-6,301
Closed -$447K
LI icon
666
Li Auto
LI
$13.1B
– –
-55,000
Closed -$1.67M
MDGL icon
667
Madrigal Pharmaceuticals
MDGL
$12.7B
– –
-18,000
Closed -$4.81M
PCRX icon
668
Pacira BioSciences
PCRX
$1.04B
– –
-181,901
Closed -$5.32M
PEN icon
669
Penumbra
PEN
$12.6B
– –
-16,171
Closed -$3.61M
PGNY icon
670
Progyny
PGNY
$2.47B
– –
-94,056
Closed -$3.59M
PHR icon
671
Phreesia
PHR
$657M
– –
-177,939
Closed -$4.26M
POWI icon
672
Power Integrations
POWI
$3.53B
– –
-71,826
Closed -$5.14M
PTCT icon
673
PTC Therapeutics
PTCT
$6.29B
– –
-167,048
Closed -$4.86M
RAPT
674
DELISTED
RAPT Therapeutics
RAPT
– –
-39,158
Closed -$2.81M
RCKT icon
675
Rocket Pharmaceuticals
RCKT
$355M
– –
-165,000
Closed -$4.45M
24 25 26
27
28

Similar funds

PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
A
AustralianSuper Melbourne, Australia $19.2B AUM 31.95% 1-Year Est. Return
MGP
M&G plc London, United Kingdom $19.4B AUM 16.7% 1-Year Est. Return
LF
Lansforsakringar Fondforvaltning Stockholm, Sweden $19.1B AUM 26.9% 1-Year Est. Return
Select Equity Group
Select Equity Group New York $19.5B AUM 17.33% 1-Year Est. Return
SOMRS
State of Michigan Retirement System Lansing, Michigan $18.9B AUM 27.96% 1-Year Est. Return
BPA
Beacon Pointe Advisors Newport Beach, California $18.9B AUM 18.9% 1-Year Est. Return
MIM
MetLife Investment Management Whippany, New Jersey $19.6B AUM 32.64% 1-Year Est. Return

Candriam SCA's Q2 2024 Portfolio in Review

As of Q2 2024, Candriam SCA held 735 positions worth $16.5B, up 5.5% from $15.6B the previous quarter. Its ten largest holdings account for 30% of the portfolio.

Candriam SCA's Q2 2024 filing shows 44 new, 335 increased, 212 reduced and 49 closed positions. Its largest new stake was Banco Macro: 754,200 shares worth $43.2M. The largest sale was Apple, an estimated $40.8M.

By sector, the portfolio is most concentrated in Technology at 33% of assets, up from 32% a quarter earlier, followed by Healthcare and Financials.

  • Candriam SCA's largest Q2 2024 buy was Banco Macro: 754,200 shares worth $43.2M.
  • Candriam SCA added most to Eli Lilly in Q2 2024, an estimated $60.1M increase.
  • Candriam SCA's biggest Q2 2024 reduction was Apple, cutting an estimated $40.8M.
  • Candriam SCA fully exited Alpine Immune Sciences Inc in Q2 2024, selling an estimated $16.5M.
  • Candriam SCA's ten largest holdings make up 30% of its $16.5B portfolio in Q2 2024.
  • Candriam SCA opened 44 new positions and closed 49 in Q2 2024.
  • Candriam SCA's portfolio value rose 5.5% quarter-over-quarter to $16.5B.

Based on Candriam SCA's 13F filing for Q2 2024, filed 5 Aug 2024.